Stockscreener 앱 받기
36.90
2.36%
0.85
시간 외 거래:
37.00
0.10
+0.27%
전일 마감가:
$36.05
열려 있는:
$36.45
하루 거래량:
2.12M
Relative Volume:
1.44
시가총액:
$2.92B
수익:
-
순이익/손실:
$-119.67M
주가수익비율:
-13.52
EPS:
-2.73
순현금흐름:
$-97.30M
1주 성능:
-4.16%
1개월 성능:
-22.04%
6개월 성능:
+147.32%
1년 성능:
+203.20%
1일 변동 폭
$35.87
$39.15
1주일 범위
$35.77
$39.22
52주 변동 폭
$8.241
$47.65
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
명칭
Mineralys Therapeutics Inc
전화
(888) 378-6240
주소
150 N. RADNOR CHESTER ROAD, RADNOR
MLYS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
36.90 | 2.85B | 0 | -119.67M | -97.30M | -2.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-11 | 개시 | Jefferies | Hold |
| 2024-07-10 | 개시 | H.C. Wainwright | Buy |
| 2024-04-02 | 개시 | Goldman | Buy |
| 2023-03-07 | 개시 | BofA Securities | Buy |
| 2023-03-07 | 개시 | Credit Suisse | Outperform |
| 2023-03-07 | 개시 | Evercore ISI | Outperform |
| 2023-03-07 | 개시 | Guggenheim | Buy |
| 2023-03-07 | 개시 | Stifel | Buy |
| 2023-03-07 | 개시 | Wells Fargo | Overweight |
모두보기
Mineralys Therapeutics Inc 주식(MLYS)의 최신 뉴스
Boothbay Fund Management LLC Sells 116,877 Shares of Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Aug Opening: Is Mineralys Therapeutics Inc stock a contrarian buyPortfolio Performance Report & Daily Technical Stock Forecast Reports - moha.gov.vn
Biotech Shake-Up: New CEO Takes Helm at Jubilant Therapeutics - MyChesCo
Mineralys hypertension drug trial featured in JAMA’s top research of 2025 - Investing.com Canada
Mineralys Therapeutics’ Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) 'Research of the Year” Roundup - The Manila Times
Mineralys (Nasdaq: MLYS) Launch-HTN Cuts BP 19.0 mmHg, Lands JAMA Research of Year - Stock Titan
Mineralys Therapeutics’ Earnings Call Highlights Positive Outlook - MSN
73,921 Shares in Mineralys Therapeutics, Inc. $MLYS Acquired by Walleye Capital LLC - MarketBeat
HighVista Strategies LLC Takes Position in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Price-Driven Insight from (MLYS) for Rule-Based Strategy - news.stocktradersdaily.com
Swiss National Bank Invests $838,000 in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
22NW LP Purchases 98,698 Shares of Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys Therapeutics, Inc. $MLYS Shares Purchased by Pale Fire Capital SE - MarketBeat
Aug Big Picture: How Mineralys Therapeutics Inc stock reacts to inflationary pressuresInsider Buying & Low Volatility Stock Suggestions - BỘ NỘI VỤ
Is Mineralys Therapeutics Inc a good long term investmentMarket Timing Techniques & High Return Investment Plans - earlytimes.in
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Wall Street Analysts Think Mineralys Therapeutics, Inc. (MLYS) Could Surge 27.55%: Read This Before Placing a Bet - sharewise.com
Mineralys Therapeutics, Inc. $MLYS Shares Sold by Quadrature Capital Ltd - MarketBeat
Is Mineralys Therapeutics Inc. stock a buy for dividend growthJuly 2025 Market Mood & Long-Term Safe Investment Ideas - Newser
How Mineralys Therapeutics Inc. stock valuations compare to rivalsQuarterly Market Summary & Daily Oversold Stock Bounce Ideas - Newser
Mineralys Therapeutics Earnings Notes - Trefis
Mineralys Awards New Hire Stock Option as Hypertension Pipeline Advances - MSN
MLYS SEC FilingsMineralys Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
This Fund Leaned Into 2025's Big Biotech Rally with a $9.5 Million Bet on Mineralys - AOL.com
AZ uses a priority review voucher for baxdrostat filing - pharmaphorum
Mineralys Therapeutics, Inc. $MLYS Shares Acquired by Geode Capital Management LLC - MarketBeat
AstraZeneca Moves Ahead of Mineralys With Fast Baxdrostat Review - Citeline News & Insights
Virtus Investment Advisers LLC Sells 7,192 Shares of Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Prudential Financial Inc. Increases Stake in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys Therapeutics (MLYS) Stock Analysis Report | Financials & Insights - Benzinga
Will Mineralys Therapeutics Inc. stock rally after Fed decisions - Newser
How Investors May Respond To Mineralys Therapeutics (MLYS) After $287.5 Million Upsized Capital Raise and New Institutional Backing - Sahm
Ensign Peak Advisors Inc Raises Holdings in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
(MLYS) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
A Look at Mineralys Therapeutics (MLYS) Valuation After Findell Capital’s Major New Investment - Yahoo Finance
Mineralys Therapeutics, Inc. $MLYS Shares Bought by Franklin Resources Inc. - MarketBeat
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Mineralys Therapeutics reports inducement award under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
ProShare Advisors LLC Takes $141,000 Position in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Sunday’s Insider Moves: Major Buys at STAA, ANVS While ROIV Sees Selling - Investing.com
Mineralys Therapeutics Insider Sold Shares Worth $43,350,000, According to a Recent SEC Filing - MarketScreener
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week - MSN
Catalys Pacific fund sells Mineralys Therapeutics shares for $43.35m By Investing.com - Investing.com Australia
Catalys Pacific fund sells Mineralys Therapeutics shares for $43.35m - Investing.com India
Mineralys Therapeutics, Inc.Common Stock (Nasdaq:MLYS) Stock Quote | PRN_FinancialWrapper | PR Newswire - Markets Financial Content
Director’s Major Stock Sale Shakes Up Mineralys Therapeutics! - TipRanks
[Form 4] Mineralys Therapeutics, Inc. Insider Trading Activity - Stock Titan
Mineralys Therapeutics Inc (MLYS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Mineralys Therapeutics Inc 주식 (MLYS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Slingsby Brian Taylor | Director |
Nov 20 '25 |
Sale |
43.35 |
1,000,000 |
43,350,000 |
7,903,838 |
1.08%
0.91%
자본화:
|
볼륨(24시간):